TACSTD2 and pancreatic neoplasm: Given that there is no molecular‐targeted therapy in the standard of care for pancreatic cancer and cholangiocarcinoma patients, TROP2‐targeted PIT is an attractive candidate for clinical trials and ultimately treatment.